Back to Atlas
APotentially durableStandard research/education caution
CMP-0027
Research tool
BPTES
Senolytic / GLS1
Senescent-cell killing and aging-dysfunction improvement in models
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Small molecule
- Primary mechanism
- Glutaminase-1 inhibition exploits senescent-cell glutaminolysis dependence
- Primary market use
- Senolytic / metabolism research
Pharmacology
- Molecular weight (Da)
- 534.6
- Oral bioavailability
- Not orally optimized; research compound
- Half-life
- ~2–12 h small-molecule class estimate
- Route tags
- Route-dependent / verify
- Evidence level
- Preclinical
- Clinical status
- Research tool
- Value-for-money score
- 4 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Prototype GLS1 inhibitor; less drug-like than telaglenastat